Originally published as JCO Early Release 10.1200/JCO.2005.02.7045 on October 31 2005
Journal of Clinical Oncology, Vol 23, No 34 (December 1), 2005: pp. 8606-8612
© 2005 American Society of Clinical Oncology.
Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies
Stefanos Bonovas,
Kalitsa Filioussi,
Nikolaos Tsavaris,
Nikolaos M. Sitaras
From the Departments of Pharmacology and Pathophysiology, School of Medicine, University of Athens; and Department of Epidemiological Surveillance and Intervention, Hellenic Center for Infectious Disease Control, Athens, Greece
Address reprint requests to Stefanos Bonovas, MD, MSc, Department of Pharmacology, School of Medicine, University of Athens, 75 Mikras Asias Str, Athens 11527, Greece; e-mail: sbonovas{at}med.uoa.gr
PURPOSE: A growing body of evidence suggests that statins may have chemopreventive potential against breast cancer. Laboratory studies demonstrate that statins induce apoptosis and reduce cell invasiveness in various cell lines, including breast carcinoma cells. However, the clinical relevance of these data remains unclear. The nonconclusive nature of the epidemiologic data prompted us to conduct a detailed meta-analysis of the studies published on the subject in peer-reviewed literature.
PATIENTS AND METHODS: A comprehensive search for articles published up until 2005 was performed; reviews of each study were conducted; and data were abstracted. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% CIs were calculated using the random and the fixed-effects models. Subgroup and sensitivity analyses were also performed.
RESULTS: Seven large randomized trials and nine observational studies (five case-control and four cohort studies) contributed to the analysis. We found no evidence of publication bias or heterogeneity among the studies. Statin use did not significantly affect breast cancer risk (fixed effects model: RR = 1.03; 95% CI, 0.93 to 1.14; random effects model: RR = 1.02; 95% CI, 0.89 to 1.18). When the analyses were stratified into subgroups, there was no evidence that study design substantially influenced the estimate of effects. Furthermore, the sensitivity analysis confirmed the stability of our results.
CONCLUSION: Our meta-analysis findings do not support a protective effect of statins against breast cancer. However, this conclusion is limited by the relatively short follow-up times of the studies analyzed. Further studies are required to investigate the potential decrease in breast cancer risk among long-term statin users.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Editorial
- Can Statin Therapy Reduce the Risk of Breast Cancer?
Victor G. Vogel
JCO 2005 23: 8553-8555
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
L. Calleros, I. Sanchez-Hernandez, P. Baquero, M. J. Toro, and A. Chiloeches
Oncogenic Ras, but not V600EB-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells
Carcinogenesis,
October 1, 2009;
30(10):
1670 - 1677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Strasak, R. M. Pfeiffer, L. J. Brant, K. Rapp, W. Hilbe, W. Oberaigner, S. Lang, W. Borena, H. Concin, G. Diem, et al.
Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172 210 men and women: a prospective 19-year follow-up study
Ann. Onc.,
June 1, 2009;
20(6):
1113 - 1120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A M Tonkin, A Forbes, and S J Haas
The evidence on trial: cholesterol lowering and cancer
Heart Asia,
March 6, 2009;
2009(2):
6 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Kumar, C. C. Benz, V. Shim, C. A. Minami, D. H. Moore, and L. J. Esserman
Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2008;
17(5):
1028 - 1033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Byers
Statins, Breast Cancer, and an Invisible Switch?
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2008;
17(5):
1026 - 1027.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Platz
Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2007;
16(11):
2175 - 2180.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bonovas, K. Filioussi, C. S. Flordellis, and N. M. Sitaras
Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients
J. Clin. Oncol.,
August 10, 2007;
25(23):
3462 - 3468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Zhang, J. Lin, N. R. Cook, I-M. Lee, J. E. Manson, J. E. Buring, and P. M. Ridker
C-Reactive Protein and Risk of Breast Cancer
J Natl Cancer Inst,
June 6, 2007;
99(11):
890 - 894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Sanchez-Martin, A. Davalos, C. Martin-Sanchez, G. de la Pena, C. Fernandez-Hernando, and M. A. Lasuncion
Cholesterol Starvation Induces Differentiation of Human Leukemia HL-60 Cells
Cancer Res.,
April 1, 2007;
67(7):
3379 - 3386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bonovas and N. M. Sitaras
Does pravastatin promote cancer in elderly patients? A meta-analysis
Can. Med. Assoc. J.,
February 27, 2007;
176(5):
649 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras
Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
J. Clin. Oncol.,
October 20, 2006;
24(30):
4808 - 4817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kim
Statin and Cancer Risks: From Tasseomancy of Epidemiologic Studies to Meta-Analyses
J. Clin. Oncol.,
October 20, 2006;
24(30):
4796 - 4797.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Campbell, L. J. Esserman, Y. Zhou, M. Shoemaker, M. Lobo, E. Borman, F. Baehner, A. S. Kumar, K. Adduci, C. Marx, et al.
Breast Cancer Growth Prevention by Statins.
Cancer Res.,
September 1, 2006;
66(17):
8707 - 8714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res.,
June 15, 2006;
12(12):
3661 - 3697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Kumar, M. Campbell, C. C. Benz, and L. J. Esserman
A Call for Clinical Trials: Lipophilic Statins May Prove Effective in Treatment and Prevention of Particular Breast Cancer Subtypes
J. Clin. Oncol.,
May 1, 2006;
24(13):
2127 - 2127.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Prowell, V. Stearns, and B. Trock
Lipophilic Statins Merit Additional Study for Breast Cancer Chemoprevention
J. Clin. Oncol.,
May 1, 2006;
24(13):
2128 - 2129.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras
In Reply
J. Clin. Oncol.,
May 1, 2006;
24(13):
2129 - 2129.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras
In Reply
J. Clin. Oncol.,
May 1, 2006;
24(13):
2130 - 2131.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras
In Reply
J. Clin. Oncol.,
May 1, 2006;
24(13):
2127 - 2128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Sprague and M. E. Wood
Statins and Breast Cancer Prevention: Time for Randomized Controlled Trials
J. Clin. Oncol.,
May 1, 2006;
24(13):
2129 - 2130.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. G. Vogel
Can Statin Therapy Reduce the Risk of Breast Cancer?
J. Clin. Oncol.,
December 1, 2005;
23(34):
8553 - 8555.
[Full Text]
[PDF]
|
|
|
|
